KISQALI FEMARA CO-PACK (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the KISQALI FEMARA CO-PACK drug offered from Novartis Pharmaceuticals Corporation. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | letrozole and ribociclib |
| SUBSTANCE NAME: | |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | |
| ROUTE: | |
| DOSAGE FORM: | KIT |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-05-04 |
| END MARKETING DATE: | 0000-00-00 |
KISQALI FEMARA CO-PACK HUMAN PRESCRIPTION DRUG Details:
| Item Description | KISQALI FEMARA CO-PACK from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: | |
| ACTIVE STRENGTH: | () |
| START MARKETING DATE: | 2017-05-04 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0909_bbb67312-e5e6-4537-a95c-59c324ab549f |
| PRODUCT NDC: | 0078-0909 |
| APPLICATION NUMBER: | NDA209935 |